Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

A. Corso; S. Mangiacavalli; L. Barbarano; L. Montalbetti; A. Mazzone; S. Fava; M. Varettoni; P. Zappasodi; E. Morra; M. Lazzarino

doi:10.1016/j.leukres.2007.11.011

Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

A. Corso, S. Mangiacavalli, L. Barbarano, L. Montalbetti, A. Mazzone, S. Fava, M. Varettoni, P. Zappasodi, E. Morra, M. Lazzarino

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.

Original language	English
Pages (from-to)	1085-1090
Number of pages	6
Journal	Leukemia Research
Volume	32
Issue number	7
DOIs	https://doi.org/10.1016/j.leukres.2007.11.011
Publication status	Published - Jul 2008

Keywords

High-dose therapy
Intensification
Multiple myeloma
Thalidomide
Up-front therapy

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2007.11.011

Cite this

Corso, A , Mangiacavalli, S, Barbarano, L, Montalbetti, L, Mazzone, A, Fava, S, Varettoni, M , Zappasodi, P, Morra, E & Lazzarino, M 2008, 'Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy', Leukemia Research, vol. 32, no. 7, pp. 1085-1090. https://doi.org/10.1016/j.leukres.2007.11.011

@article{8182e5f5b0324b2796ddcdd38e4f0f3c,

title = "Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy",

abstract = "Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.",

keywords = "High-dose therapy, Intensification, Multiple myeloma, Thalidomide, Up-front therapy",

author = "A. Corso and S. Mangiacavalli and L. Barbarano and L. Montalbetti and A. Mazzone and S. Fava and M. Varettoni and P. Zappasodi and E. Morra and M. Lazzarino",

year = "2008",

month = jul,

doi = "10.1016/j.leukres.2007.11.011",

language = "English",

volume = "32",

pages = "1085--1090",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

AU - Corso, A.

AU - Mangiacavalli, S.

AU - Barbarano, L.

AU - Montalbetti, L.

AU - Mazzone, A.

AU - Fava, S.

AU - Varettoni, M.

AU - Zappasodi, P.

AU - Morra, E.

AU - Lazzarino, M.

PY - 2008/7

Y1 - 2008/7

N2 - Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.

AB - Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.

KW - High-dose therapy

KW - Intensification

KW - Multiple myeloma

KW - Thalidomide

KW - Up-front therapy

UR - http://www.scopus.com/inward/record.url?scp=41949136010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949136010&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.11.011

DO - 10.1016/j.leukres.2007.11.011

M3 - Article

C2 - 18096226

AN - SCOPUS:41949136010

SN - 0145-2126

VL - 32

SP - 1085

EP - 1090

JO - Leukemia Research

JF - Leukemia Research

IS - 7

ER -

Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this